Table 3.
Multivariable analysis of factors associated with duration of SARS‐CoV‐2 RNA shedding in 181 patients during 21 Jan 2020 to 16 Mar 2020 from Anhui, China
| Variable | Unadjusted HR (95% CI) | P | Adjusted HR (95% CI) | P |
|---|---|---|---|---|
| Age | 0.995 (0.984‐1.006) | .347 | 0.999 (0.988‐1.011) | .896 |
| Male sex | 0.831 (0.618‐1.118) | .222 | 0.759 (0.559‐1.031) | .078 |
| Current smokers | 0.930 (0.577‐1.499) | .767 | … | … |
| Hypertension | 0.984 (0.639‐1.516) | .943 | … | … |
| Diabetes | 0.854 (0.475‐1.535) | .598 | … | … |
| Bacterial pneumonia | 0.929 (0.667‐1.293) | .663 | … | … |
| Severe status of COVID‐19 | 0.903 (0.621‐1.314) | .595 | … | … |
| White blood cell count, ×109/L | 1.026 (0.961‐1.096) | .440 | … | … |
| IL‐6, pg/mL | 1.000 (0.998‐1.001) | .578 | … | … |
| Corticosteroids | 0.829 (0.593‐1.159) | .272 | … | … |
| Antibiotics | 0.802 (0.597‐1.076) | .141 | 0.761 (0.561‐1.032) | .079 |
| Lopinavir/ritonavir monotherapy | 0.868 (0.645‐1.170) | .353 | … | … |
| Lopinavir/ritonavir + IFN‐α combination therapy | 1.645 (1.163‐2.327) | .005 | 1.649 (1.162‐2.339) | .005 |
| Lopinavir/ritonavir + IFN‐α + arbidol combination therapy | 0.636 (0.394‐1.027) | .064 | 0.648 (0.380‐1.105) | .111 |
| Time from illness onset to antiviral treatment in da | 0.982 (0.968‐0.995) | .008 | 0.976 (0.962‐0.990) | .001 |
Note: Variables with HR < 1 increase the duration of SARS‐CoV‐2 shedding. HRs in multivariable analysis were adjusted for age and sex.
Abbreviations: CI, confidence interval; COVID‐19, coronavirus disease‐2019; HR, hazard ratio; IFN, interferon; IL‐6, interleukin‐6; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2.
a
By use of the time‐dependent Cox regression model.